TargetBeta
CSF3
colony stimulating factor 3 · also MGC45931, GCSF, G-CSF, C17orf33 · Receptor ligands
1 program in company-led studies act on CSF3, from 1 company: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| pegfilgrastimrule | Amgen | phase 4 | 522 running | CSF3R | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Breast Neoplasms, 1 program
- Febrile Neutropenia, 1 program
- Lymphoma, 1 program
- Lymphoma, Non-Hodgkin, 1 program
- Neutropenia, 1 program
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.